SecBot SecBot
PREM14A ·Filed Apr 15, 2026

SEM

SELECT MEDICAL HOLDINGS CORP
BULLISH
Impact 8/10
Horizonmonths Processed7mo ago SEC0001104659-26-043505
Preliminary proxy statement (merger-related)
Actionable Insight ▲ Bullish

The merger represents a significant premium and has strong support from the Special Committee and financial advisor. Shareholders should consider voting in favor of the merger proposal. The transaction is expected to close in mid-2026, subject to regulatory and shareholder approval.

DirectionBullish
Confidencehigh
Horizonmonths

How the stock moved after the report

BULLISH VIEWSTOCK ABOVE ENTRY AT T+20
Entry
$16.38
T+0 close · Apr 15, 2026 · via day close
Latest settled
+0.43%
T+20 · $16.45
Vs SPY
−5.62%
α at T+20
Next horizon
T+60
due 4mo ago
  1. T+0 · Apr 15 $16.38entry
  2. T+1 · 7mo ago +0.06%α −0.19% · $16.39
  3. T+5 · 7mo ago +0.31%α −1.33% · $16.43
  4. T+20 · 6mo ago +0.43%α −5.62% · $16.45
  5. T+60 · due 4mo ago Pending
Loading chart...

Executive Summary

Select Medical Holdings Corporation (SEM) is being acquired by a consortium led by Welsh, Carson, Anderson & Stowe (WCAS) and company executives Robert Ortenzio and Martin Jackson in a going-private transaction. The merger agreement, valued at $2.05 billion, offers $16.50 per share in cash, representing an 18% premium over the unaffected share price. The Special Committee, with assistance from financial advisor Goldman Sachs, unanimously recommended the deal as fair and in the best interests of unaffiliated shareholders. The transaction is expected to close in mid-2026 pending shareholder and regulatory approval.

Key Financial Metrics

Deal Value
$2.0B
Premium
18%
Deal Type
merger

Key Facts

  • Proposed acquisition price of $16.50 per share in cash
  • 18% premium over the unaffected share price of $14.01 as of November 24, 2025
  • 25% premium over the 90-day volume-weighted average price
  • Goldman Sachs provided a fairness opinion supporting the transaction
  • Special Committee unanimously recommended the deal
  • Transaction valued at $2.05 billion including equity rollover

Financial Impact

Cash consideration of $16.50 per share, representing an 18% premium over the unaffected price

revenueepsdilution

Risk Factors

  • Regulatory approval risk
  • Shareholder approval risk
  • Potential for competing bids

Market Snapshot

Exchange
NYSE
Sector
Services-Hospitals

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
PREM14A Filing (Primary)0001104659-26-043505
Document: tm268269d1_ex-filingfees.htm0001104659-26-043505
Document: 0001104659-26-043505-index-headers.html0001104659-26-043505
Document: 0001104659-26-043505-index.html0001104659-26-043505
Document: 0001104659-26-043505.txt0001104659-26-043505

Track record

8 reports on SEM

Performance horizon

The track record builds as more bullish or bearish reports settle.

Filters
  1. Jul 13, 202618w ago 15-12G Neutral 4/10 No price data
  2. Jul 1, 202619w ago 25-NSE Neutral 9/10 Entry $16.52 No price data
  3. Jul 1, 202619w ago 8-K Bullish 8/10 Entry $16.52 No price data
  4. Jun 26, 202620w ago 8-K Bullish 7/10 Entry $16.53 No price data
  5. Apr 30, 202628w ago 8-K Bearish 6/10 Entry $16.38 to $16.51 ▼ −0.81% +4.45% vs SPY
  6. Apr 15, 202630w ago PREM14A Bullish 8/10 Viewing Entry $16.38 to $16.45 ▲ +0.43% −5.62% vs SPY
  7. Mar 4, 202636w ago DEFA14A Neutral 3/10 Entry $16.25 to $16.29 ▲ +0.25% +4.66% vs SPY
  8. Mar 3, 202636w ago DEFA14A Bullish 9/10 Entry $16.26 to $16.29 ▲ +0.18% +4.59% vs SPY
Showing 8 of 8

US Market Status

Market Closed · Opens in 9h 7m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 15, 2026